Browse Internal Medicine Articles by Topic

Fecal Microbiota, live-jslm (Rebyota)

Rebyota can be prescribed to prevent recurring Clostridioides difficile infection for patients age 18 years and older who are following antibiotic treatment for recurring episodes.

Is Screening for Atrial Fibrillation Cost Effective?

Self-screening for atrial fibrillation in elderly individuals could lead to lower stroke rates, prevent bleeding-related hospitalizations, and save money.

COVID-19: Beware Remdesivir Resistance

Researchers reported two immunosuppressed renal transplant recipients with persistent SARS-CoV-2 infection in association with the new emergence of mutations in RNA-dependent RNA polymerase after remdesivir treatment.

Triglyceride-Lowering Therapy and Cardiovascular Events

Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.

Is Red Meat Really Unhealthy?

A thorough review of the evidence raises questions about the health risks of eating unprocessed red meat.

Body Weight Decline in Cognitively Intact Older Adults May Predict Future Cognitive Impairment

Among cognitively intact individuals, those who developed mild cognitive impairment (MCI) recorded faster body mass index (BMI) decline and significantly lower BMI seven years before MCI diagnosis.

Teplizumab-mzwv Injection (Tzield)

Teplizumab can be prescribed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients age 8 years and older with stage 2 type 1 diabetes.

It’s Not All About the Cough

Be careful about relying on clinical queries that focus on the presence of cough for two or more weeks, which could lead to delays in the diagnosis of nearly half of pulmonary tuberculosis cases.

Is Routine Stress Testing After Coronary Revascularization Necessary?

A multicentered study of routine stress testing at one year post-percutaneous coronary revascularization compared to usual care in patients with at least one high-risk coronary anatomic or clinical feature failed to show improved clinical outcomes at two years follow-up.

Apixaban for Venous Thromboembolism in Patients with End-Stage Kidney Disease

There is a lower risk of bleeding for those taking apixaban during venous thromboembolism treatment compared to warfarin in patients with end-stage kidney disease.